The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in ...

Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and AmylyxAppointment intended to accelerate the ...

The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...

Connecticut physician Anatoly Braylovsky, MD, was sentenced to 7.5 years in prison for distributing an excessive amount of ...

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal ...

Several teams of medical researchers are currently testing new therapies for slowing or stopping the excess or runaway bone ...

Living kidney donors and nondonors have similar risks for hypertension and albuminuria, according to a study published online ...

Using an innovative analysis technique, researchers identified antinephrin autoantibodies as markers of difficult to diagnose ...

The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to ...

The Food and Drug Administration said Tuesday that Bkemv, a monoclonal antibody, had been approved for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder, and atypical hemolytic ...

Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...

Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...